Gary A. Weisman

Gary A. Weisman

Auto-generated profile, based on publicly available information

Gary A. Weisman

University of Missouri

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KJKimberly Jasmer
Kimberly Jasmer
KGKristy E. Gilman
Kristy E. Gilman
KFKevin Muñoz Forti
Kevin Muñoz Forti
GWGary A. Weisman
Gary A. Weisman
KLKirsten H. Limesand
Kirsten H. Limesand
Salivary glands sustain collateral damage following radiotherapy (RT) to treat cancers of the head and neck, leading to complications, including mucositis, xerostomia and hyposalivation. Despite salivary gland-sparing techniques and modified dosing strategies, long-term hypofunction remains a significant problem. Current therapeutic interventions provide temporary symptom relief, but do not address irreversible glandular damage. In this review, we summarize the current understanding of mechanisms involved in RT-induced hyposalivation and provide a framework for future mechanistic studies. One glaring gap in published studies investigating RT-induced mechanisms of salivary gland dysfunction concerns the effect of irradiation on adjacent non-irradiated tissue via paracrine, autocrine and direct cell–cell interactions, coined the bystander effect in other models of RT-induced damage. We hypothesize that purinergic receptor signaling involving P2 nucleotide receptors may play a key role in mediating the bystander effect. We also discuss promising new therapeutic approaches to prevent salivary gland damage due to RT.

24 September 2011 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
WSWenwen Sheng
Wenwen Sheng
YZYijia Zong
Yijia Zong
AMArwa Mohammad
Arwa Mohammad
DADeepa Ajit
Deepa Ajit
JCJiankun Cui
Jiankun Cui
GSGrace Y Sun
Grace Y Sun
Background: Activation of glial cells, including astrocytes and microglia, has been implicated in the inflammatory responses underlying brain injury and neurodegenerative diseases including Alzheimer's and Parkinson's diseases. Although cultured astrocytes and microglia are capable of responding to pro-inflammatory cytokines and lipopolysaccharide (LPS) in the induction and release of inflammatory factors, no detailed analysis has been carried out to compare the induction of iNOS and sPLA2-IIA. In this study, we investigated the effects of cytokines (TNF-alpha, IL-1beta, and IFN-gamma) and LPS + IFN-gamma to induce temporal changes in cell morphology and induction of p-ERK1/2, iNOS and sPLA2-IIA expression in immortalized rat (HAPI) and mouse (BV-2) microglial cells, immortalized rat astrocytes (DITNC), and primary microglia and astrocytes. Methods/Results: Cytokines (TNF-alpha, IL-1beta, and IFN-gamma) and LPS + IFN-gamma induced a time-dependent increase in fine processes (filopodia) in microglial cells but not in astrocytes. Filopodia production was attributed to IFN-gamma and was dependent on ERK1/2 activation. Cytokines induced an early (15 min) and a delayed phase (1 ~ 4 h) increase in p-ERK1/2 expression in microglial cells, and the delayed phase increase corresponded to the increase in filopodia production. In general, microglial cells are more active in responding to cytokines and LPS than astrocytes in the induction of NO. Although IFN-gamma and LPS could individually induce NO, additive production was observed when IFN-gamma was added together with LPS. On the other hand, while TNF-alpha, IL-1beta, and LPS could individually induce sPLA2-IIA mRNA and protein expression, this induction process does not require IFN-gamma. Interestingly, neither rat immortalized nor primary microglial cells were capable of responding to cytokines and LPS in the induction of sPLA2-IIA expression. Conclusion: These results demonstrated the utility of BV-2 and HAPI cells as models for investigation on cytokine and LPS induction of iNOS, and DITNC astrocytes for induction of sPLA2-IIA. In addition, results further demonstrated that cytokine-induced sPLA2-IIA is attributed mainly to astrocytes and not microglial cells.

1 May 2016 in Neuropharmacology
Verified
Journal Article
Closed access
LWLucas T. Woods
Lucas T. Woods
DADeepa Ajit
Deepa Ajit
JCJean M. Camden
Jean M. Camden
LELaurie Erb
Laurie Erb
GWGary A. Weisman
Gary A. Weisman

31 August 2005 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
MWMin Wang
Min Wang
QKQiongman Kong
Qiongman Kong
FGFernando A. Gonzalez
Fernando A. Gonzalez
GSGrace Sun
Grace Sun
LELaurie Erb
Laurie Erb
GWGary A. Weisman
Gary A. Weisman
Astrocytes become activated in response to brain injury, as characterized by increased expression of glial fibrillary acidic protein (GFAP) and increased rates of cell migration and proliferation. Damage to brain cells causes the release of cytoplasmic nucleotides, such as ATP and uridine 5′‐triphosphate (UTP), ligands for P2 nucleotide receptors. Results in this study with primary rat astrocytes indicate that activation of a G protein‐coupled P2Y2 receptor for ATP and UTP increases GFAP expression and both chemotactic and chemokinetic cell migration. UTP‐induced astrocyte migration was inhibited by silencing of P2Y2 nucleotide receptor (P2Y2R) expression with siRNA of P2Y2R (P2Y2R siRNA). UTP also increased the expression in astrocytes of αVβ3/5 integrins that are known to interact directly with the P2Y2R to modulate its function. Anti‐αV integrin antibodies prevented UTP‐stimulated astrocyte migration, suggesting that P2Y2R/αV interactions mediate the activation of astrocytes by UTP. P2Y2R‐mediated astrocyte migration required the activation of the phosphatidylinositol‐3‐kinase (PI3‐K)/protein kinase B (Akt) and the mitogen‐activated protein kinase/extracellular signal‐regulated kinase (MEK/ERK) signaling pathways, responses that also were inhibited by anti‐αV integrin antibody. These results suggest that P2Y2Rs and their associated signaling pathways may be important factors regulating astrogliosis in brain disorders.

1 October 2017 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MKMahmoud G. Khalafalla
Mahmoud G. Khalafalla
LWLucas T. Woods
Lucas T. Woods
JCJean M. Camden
Jean M. Camden
AKAslam A. Khan
Aslam A. Khan
KLKirsten H. Limesand
Kirsten H. Limesand
GWGary A. Weisman
Gary A. Weisman
Salivary gland inflammation is a hallmark of Sjögren's syndrome (SS), a common autoimmune disease characterized by lymphocytic infiltration of the salivary gland and loss of saliva secretion, predominantly in women. The P2X7 receptor (P2X7R) is an ATP-gated nonselective cation channel that induces inflammatory responses in cells and tissues, including salivary gland epithelium. In immune cells, P2X7R activation induces the production of proinflammatory cytokines, including IL-1β and IL-18, by inducing the oligomerization of the multiprotein complex NLRP3-type inflammasome. Here, our results show that in primary mouse submandibular gland (SMG) epithelial cells, P2X7R activation also induces the assembly of the NLRP3 inflammasome and the maturation and release of IL-1β, a response that is absent in SMG cells isolated from mice deficient in P2X7Rs (P2X7R−/−). P2X7R-mediated IL-1β release in SMG epithelial cells is dependent on transmembrane Na+ and/or K+ flux and the activation of heat shock protein 90 (HSP90), a protein required for the activation and stabilization of the NLRP3 inflammasome. Also, using the reactive oxygen species (ROS) scavengers N-acetyl cysteine and Mito-TEMPO, we determined that mitochondrial reactive oxygen species are required for P2X7R-mediated IL-1β release. Lastly, in vivo administration of the P2X7R antagonist A438079 in the CD28−/−, IFNγ−/−, NOD.H-2h4 mouse model of salivary gland exocrinopathy ameliorated salivary gland inflammation and enhanced carbachol-induced saliva secretion. These findings demonstrate that P2X7R antagonism in vivo represents a promising therapeutic strategy to limit salivary gland inflammation and improve secretory function.

1 April 2012 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
GWGary A. Weisman
Gary A. Weisman
JCJean M. Camden
Jean M. Camden
TPTroy S. Peterson
Troy S. Peterson
DADeepa Ajit
Deepa Ajit
LWLucas T. Woods
Lucas T. Woods
LELaurie Erb
Laurie Erb